DED Magnified: A Real-World Case Library - Case 1

Activity Description and Purpose

In this first case of the series, Dr Walter O. Whitley describes the diagnosis and treatment of a patient with dry eye disease due to meibomian gland dysfunction, along with the latest clinical evidence on new treatments for dry eye disease.

Target Audience

This educational activity is intended for ophthalmologists and optometrists.

Learning Objectives

After completing this activity, participants will be better able to:
  • Review clinical evidence of approved treatments for dry eye disease
  • Design evidence-based treatment plans for persons with meibomian gland dysfunction–associated dry eye disease

 

Course summary
Available credit: 
  • 0.25 AMA PRA Category 1 Credit™
  • 0.25 COPE
  • 0.25 Participation
Course opens: 
12/15/2023
Course expires: 
12/31/2024

Faculty

Walter O. Whitley, OD, MBA, FAAO
Director, Optometric Services
Virginia Eye Consultants
Virginia Beach, Virginia

Disclosure Policy

MedEdicus adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CME activity, including faculty, planners, reviewers, or others, are required to disclose all financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been identified and mitigated by MedEdicus prior to the commencement of the activity.

Faculty

Walter O. Whitley, OD, MBA, is a consultant for Alcon, Aldeyra Therapeutics, Allergan, Apellis Pharmaceuticals, Bruder Healthcare, Dompé US, Inc, Eyenovia, Inc, Heru, Inc, Iveric Bio, Inc, Mediprint, Novartis Pharmaceuticals Corporation, Oyster Point Pharma, Inc, Regener-Eyes, Tarsus Pharmaceuticals, Inc, and Thea Pharmaceuticals; is an advisory board member of Alcon, Allergan, Bausch & Lomb Incorporated, Bruder Healthcare, Oyster Point Pharma, Inc, ScienceBased Health, Tarsus Pharmaceuticals, Inc, and Visus Therapeutics; is on the speakers bureau for Alcon, Allergan, Bausch & Lomb Incorporated, Oyster Point Pharma, Inc, and Sun Pharmaceutical Industries, Inc; and is a contracted researcher for Heru.

Peer Reviewer

This activity was peer reviewed. The peer reviewer has no relevant commercial relationships to disclose.

Planners, Managers, and Writers

MedEdicus planners, managers, and writers have no relevant commercial relationships to disclose.

Accreditation Statement

 MedEdicus LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation Statement

MedEdicus LLC designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

COPE approved for 0.25 CE credit for optometrists.
COPE Course ID: 88779-TD (Asynchronous)
COPE Course Category: Treatment/Management of Ocular Disease

Administrator:

This activity, COPE Activity Number 127406, is accredited by COPE for continuing education for optometrists.

Disclosure of Commercial Support

MedEdicus has received commercial support from Bausch & Lomb Incorporated for this activity in the form of an unrestricted educational grant.

The content of this ACCME-/COPE-accredited CME/CE activity was planned and prepared independently by MedEdicus without input from members of an ineligible company.

Off-Label Discussion

This educational activity may include discussion of unlabeled and/or investigational uses of drugs and devices. Please refer to the official prescribing information for each drug or device discussed in this activity for approved dosing, indications, and warnings.

Provider Contact Information

For questions about this educational activity, please contact MedEdicus LLC at info@mededicus.com.

Disclaimer

The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of State University of New York College of Optometry, MedEdicus LLC, or Bausch & Lomb Incorporated.

This CME/CE activity is copyrighted to MedEdicus LLC ©2023. All rights reserved. 302.2A

Available Credit

  • 0.25 AMA PRA Category 1 Credit™
  • 0.25 COPE
  • 0.25 Participation
Please login or register to take this course.

Clicking Register/Take course indicates that you have reviewed the CME/CE information for this activity.